What Made Insulin’s Prices Fall?
Examining the reasons for the recent drop in insulin prices to $35 for a 1-month supply, a Perspectives author writes: “Given the constellation of factors
Michael Posey
April 20, 2023
Examining the reasons for the recent drop in insulin prices to $35 for a 1-month supply, a Perspectives author writes: “Given the constellation of factors
Health technology assessment (HTA) organizations in Canada, France, and Germany give low added benefit ratings to many drugs that are top sellers in the U.S.
Fee-for-service Medicare beneficiaries with self-reported functional impairments and phenotypic frailty had higher subsequent healthcare costs, a prospective cohort study shows. The differences remained even after
The use of new-generation antiobesity medications in older adults presents “challenges and uncertainty” to the Medicare Part D program, Perspective authors write: “The burden of
In a Perspective article calling for better systems of prior authorization for prescription drugs, authors write that Medicare Part D is a good place to
Less clinical benefit and higher drug costs are significant predictors that a manufacturer will use direct-to-consumer advertising in its marketing efforts, a study shows. “Direct-to-consumer
Patients appreciate “accurate, real-time information on medication costs to inform decision-making,” researchers report. While healthcare providers can use real-time benefit tools (RTBTs) to facilitate conversations
Receiving substantially higher reimbursements while providing marginally better care, large health systems in the U.S. delivered a disproportionate share of the nation’s medical services in
Participation of for-profit hospitals in the U.S. in graduate medical education (GME) increased during the 2011–2020 decade, researchers report, producing $832.8 million in federal subsidies
The implications of the Federal Trade Commission (FTC) investigation of pharmacy benefits managers (PBMs) remain to be seen, write the authors of a Viewpoint article